EUFEPS Workshop

Opportunities and Challenges
in Vaccine Delivery

September 15-17 • 2008 • University of Geneva • Site d’Archamps • France

Index » Click for Venue Information » Click for Registration on-line » Click for the Final Programme including the time-schedule (PDF)   Download the 1st Announcement Download the 2nd Announcement To read PDF files you will need the software plug-in Acrobat Reader, which is a free shareware from Adobe. Click here if you wish to download the shareware.

Scope & Aim & Objectives
This workshop will combine basic immunological aspects as well as contributions from an end-user perspective with vaccine delivery issues. Moreover, it will provide scientists and managers from academia and industry, involved in the vaccine development process, with first-hand information on the challenges and opportunities in vaccine delivery.

The Workshop opens on Monday, September 15, 2008, at 09:00 (Pre-registration on Sunday, September 14) and it closes on Wednesday, September 17, at 12:30.

Workshop Sessions
The Workshop is structured into five Speaker Sessions and four Breakout Sessions.
Speaker Sessions include:

• Vaccine delivery: Basic principles
• Routes of administration: Alternatives for the needle
• Pharmaceutical aspects: Delivery systems, formulation,
  characterisation and stability
• Case studies
• Regulatory, industrial and academic perspectives

The breakouts sessions offer a discussion forum for problem solving, conclusions and recommendations regarding ‘hot’ vaccine delivery topics, like choice of the delivery route, how to choose the ‘right’ antigens and adjuvants, formulation, characterisation and stability issues, as well as clinical aspects.

Scientific & Planning Committee
Gerrit Borchard, Co-chair, University of Geneva, Geneva CH
Wim Jiskoot, Co-chair, Leiden/Amsterdam Center for Drug Research, Leiden NL
Joke Bouwstra, CRS, Leiden University, Leiden NL
Daan JA Crommelin, Top Institute Pharma/EUFEPS, Leiden NL
Vinod P Shah, FIP, North Potomac MD USA
Hans H Lindén, EUFEPS, Stockholm SE
Kyung-Dall Lee, AAPS, Arlington VA USA
Yvonne Perrie, Aston University, Birmingham UK
Thomas Rades, University of Otago, Dunedin NZ
Derek O’Hagan, Novartis Vaccines, Siena IT
Martin Bachmann, Cytos Biotechnology, Schlieren CH
Nathalie Garçon, GlaxoSmithKline, Rixensart BE

Poster Contributions
Scientific contributions relating to the scope and aim of the Workshop will be welcome and considered for poster presentations. Abstracts should be submitted to the EUFEPS Secretariat, both as an email attachment and as a hard copy.
Abstract submission deadline will be July 31, 2008.

Click for Editorial Instructions.

Exhibition Information
Companies are welcome to participate as exhibitors at this Workshop, providing an opportunity to meet researchers and experts in this field. It offers every opportunity in facilitating contacts and interactions, including predicting needs and shaping future collaboration.

Sponsorship Opportunities
To sponsor this Workshop and by this enable additional quality meetings on key topics, contact the EUFEPS President, Daan JA Crommelin (daan.crommelin@tipharma.com) or the Executive Director, Hans H Lindén (hans.linden@eufeps.org) or the Project Manager, Annika Nyman (annika.nyman@eufeps.org)

Language
English will be the language of this Workshop.
No simultaneous translation will be provided.

Organisers
EUFEPS (European Federation for Pharmaceutical Sciences) was founded 1991. Its mission is to advance excellence in the pharmaceutical sciences and innovative drug research and to represent the interests of scientists engaged in drug research and development, drug regulation and drug policymaking. Currently, it links scientific societies and associations in 24 European countries. In addition, there are member institutions and more than 600 individual members of EUFEPS.

FIP (International Pharmaceutical Federation) is the world-wide federation of national pharmaceutical (professional and scientific) associations, with a mission to represent and serve pharmacy and pharmaceutical sciences around the globe. Through its member associations, FIP connects, represents and serves more a million pharmacists and pharmaceutical scientists around the world. FIP was founded in The Hague, The Netherlands, in 1912 and still has its central office in The Hague. Although FIP is a federation of associations, any pharmacist or pharmaceutical scientist can apply to become an Individual Member of FIP. For more information on FIP and its activities, please visit www.fip.org

Preliminary Programme

Monday, September 15, 2008

Welcome, Introduction and Opening Remarks
Wim Jiskoot, Conference Co-Chair, Leiden/Amsterdam Center for Drug Research, Leiden NL
Gerrit Borchard, Conference Co-Chair, University of Geneva, Geneva CH

Keynote Lecture  

• Parenteral versus nonparenteral delivery
  Martin Friede, World Health Organisation, Geneva CH

Session I: Vaccine delivery: Basic principles

• Immunological principles
  Martin Bachmann, Cytos Biotechnology AG, Schlieren CH
• Dendritic cells as targets for vaccine delivery
  Derek Hart, Mater Medical Research Institute, South Brisbane AU
• Adjuvant mechanisms
  Virgil EJC Schijns, Intervet Int BV, NL
• Reversed vaccinology
  Derek T O’Hagan, Novartis Vaccines and Diagnostics, Siena IT

Session II: Routes of administration: Alternatives for the needle

• Oral vaccine delivery
  Ed Lavelle, Trinity College Dublin, Dublin IE
• Nasal vaccine delivery
  Wim Jiskoot, Leiden/Amsterdam Center for Drug Research, Leiden NL
• Pulmonary vaccine delivery
  Gerrit Borchard, University of Geneva, Geneva CH
• Dermal vaccine delivery
  Joke Bouwstra, Leiden University, Leiden NL

Breakout Sessions

POSTER SESSION I
Bus shuttle from Site d’Archamps for a Welcome Dinner in Geneva.

Tuesday, September 16, 2008

Session III: Pharmaceutical aspects: Delivery systems, formulation, characterisation, stability

• MF59: Adjuvant or delivery vehicle?
  Derek T O’Hagan, Novartis Vaccines and Diagnostics, Siena IT
• Single shot vaccines
  Bas Kremer, OctoPlus Technologies, Leiden NL
• Colloidal versus implantable vaccines
  Thomas Rades, University of Otago, Dunedin NZ
• DNA vaccine delivery systems
  Yvonne Perrie, Aston University, Birmingham UK
• Delivery issues for allergy vaccines
  Bruno Gander, ETH, Zurich CH

Session IV: Case studies

• Vaccine delivery via needle free injection
  Mark Kendall, University of Queensland, Brisbane AU
• Early-life immunisation: Which challenges for vaccine formulation?
  Claire-Anne Siegrist, University of Geneva, Geneva CH
• Additional case study considered

Breakout Sessions

POSTER SESSION II
Drinks and Snacks

Wednesday, September 17, 2008

Session V: Vaccine delivery: ‘Real world’ perspectives

• Regulatory perspective
  Brijesh Patel, Medicines and Healthcare products Regulatory Agency, London UK
• Regulatory perspective
  Roland Dobbelaer, Lokeren BE
• Industrial perspective
  Ronald Zurbriggen, Pevion Biotech Ltd, Bern CH
• Academic perspective
  Dennis Christensen, Staten Serum Institute, Copenhagen DK

Report from break-out sessions

Closing remarks 
Gerrit Borchard, Conference Co-Chair, University of Geneva, Geneva CH
Wim Jiskoot, Conference Co-Chair, Leiden/Amsterdam Center for Drug Research, Leiden NL

Registration
The registration fee includes all workshop documentation, all coffee breaks, two lunches and the Welcome Dinner. The cost for travel and hotel accommodation is not included in the registration fee.

Click for Registration on-line

Workshop Registration Fees (EUR)

• Gold Corporate Sponsorship Rate: 10 % reduction of
  fee/s (AstraZeneca, GlaxoSmithKline, Pfizer)
• Silver Corporate Sponsorship Rate: 5 % reduction of
  fee/s (BayerHealthCare)

Disclaimer/Liability
The Organising Committee and Congrex Sweden AB accept no liability for any injuries/losses incurred by the participants and/or accompanying persons, nor loss of, or damage to, any luggand and/or personal belongings.

Hotel Rates

Useful Addresses

EUFEPS Member Societies

EUFEPS Sponsors